UNSPSC 51263001: Dapiprazole

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C19H27N5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5RNZ8GJO7K, chemically known as 5,6,7,8-tetrahydro-3-(2-(4-o-tolyl-1-piperazinyl)ethyl)-s-triazolo(4,3-a)pyridine monohydrochloride but generally known as dapiprazole, which bears US NIH Compound Identifier 91269. European Medicines Agency schedules Dapiprazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06906MIG.

UNSPSC 51263001 Dapiprazole is a Commodity code that nominally refers to a specific pharmaceutical agent, but the recent state and local opportunities tagged under it show procurement of naloxone, safe drug deactivation systems, and broader direct-to-manufacturer prescription fulfillment programs — a mismatch that signals limited relevance of the code's nominal scope to actual buying activity. State and local health and human services agencies are the primary issuing bodies. Seminole County, Florida procures naloxone and drug deactivation systems through competitive sealed bidding to support community health initiatives, while the Texas Health and Human Services Commission is exploring vendor capacity for direct-to-manufacturer prescription programs through exploratory request for information. The work being solicited spans pharmaceutical procurement and supply-chain management for health departments and state pharmacy benefit programs, with emphasis on delivery logistics, cost management, and vendor compliance with drug-free workplace and federal environmental regulations.

Seminole County's IFB60459723LAS, posted June 30, 2026, seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023 and quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; the contract carries a two-year initial term with one-year renewal option and requires workers' compensation, commercial general liability, and professional liability insurance. Texas HHS Commission's RFI HHS0017013, posted April 3, 2026, is gathering vendor intelligence on direct contracting with pharmaceutical manufacturers for self-insured health plans and state employee programs, with no formal evaluation criteria or award value specified at this preliminary stage. The code shows limited recent activity, and the mismatch between the nominal dapiprazole commodity and the actual naloxone and prescription-management work being procured suggests that opportunities tagged under this code may reflect data-classification inconsistencies rather than sustained procurement demand for the specific pharmaceutical agent.